BRIEF—ReciBioPharm secures grant from Gates Foundation

ReciBioPharm, a division of Sweden-headquartered contract development and manufacturing organization (CDMO) Recipharm, has been awarded a three-year grant from the Bill & Melinda Gates Foundation (Gates Foundation), to enhance RNA production technologies.

ReciBioPharm’s platform will improve the scalability, quality, and accessibility of RNA-based medicines and will help advance its goal of developing fully integrated, continuous processes across the biomanufacturing industry.

Vikas Gupta, President of ReciBioPharm, said: “This grant represents a significant milestone in our commitment to advancing RNA manufacturing technologies that meet FDA standards. We are proud to lead this transformative effort, expanding access to RNA-based solutions for underserved regions.”